Taken together, these results support the hypothesis that CD4+ and CD8+ T-cell responses should be monitored together during TB treatment, as successful mycobacterial clearance involves CD8+ T-cell effectors, which in turn require CD4+ T-cell involvement (56). The gene discussed is CD4; the disease is tuberculosis.